SUBSCRIBE
SUBSCRIBE

Shuttle Pharmaceuticals

IN THE PRESS
Press Releases
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
March 13, 2025
 · 
4 min read
Press Releases
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
March 12, 2025
 · 
4 min read
Press Releases
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
February 27, 2025
 · 
4 min read
Press Releases
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
January 21, 2025
 · 
5 min read
Press Releases
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 8, 2025
 · 
4 min read
Press Releases
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
December 20, 2024
 · 
4 min read
Press Releases
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
November 26, 2024
 · 
5 min read
Press Releases
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
November 14, 2024
 · 
6 min read
Press Releases
Shuttle Pharma Pays Off Senior Secured Convertible Note
October 30, 2024
 · 
4 min read
Press Releases
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
October 30, 2024
 · 
4 min read
Load More
JOBS